All In Biotech

Drug Trial Radar · NCT07822334

A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

A Phase I, Randomized, Investigator and Participant-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of RO7830698 in Healthy Participants (Part 1) and in Participants With Chronic Obstructive Pulmonary Disease (Part 2)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Oct 28, 2026

Primary completion

Oct 11, 2028

Study completion Jun 20, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive pulmonary disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Healthy Participants

Interventions

  • RO7830698Drug

    Participants will receive RO7830698 as per the schedule described in the protocol.

  • PlaceboDrug

    Participants will receive placebo as per the schedule described in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence and Severity of Adverse Events (AEs)Time frame: Up to approximately 50 weeks
  2. Part 2: Incidence and Severity of AEsTime frame: Up to approximately 44 weeks
  3. Part 1: Incidence of Dose-limiting Adverse Events (DLAEs)Time frame: Up to approximately 50 weeks
  4. Part 2: Incidence of DLAEsTime frame: Up to approximately 44 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medicines Evaluation Unit

    Wythenshawe, Greater Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.